

Codeine

:Selected References

- Akhigbe RE, et al. 2022. Codeine alters female reproductive function by targeting ovarian steroidogenesis and folliculogenesis via the induction of oxidative stress, inflammation, and apoptosis, *Reproductive Toxicology* 109: 1-9.
- Azuine RE, et al. 2019. Prenatal risk factors and perinatal and postnatal outcomes associated with maternal opioid exposure in an urban, low-income, multiethnic US population. *JAMA network* 2(6): e196405-196405.
- Berlin CM, Jr, et al. 2009. Safety issues of maternal drug therapy during breastfeeding. *Clinical pharmacology and therapeutics* 85(1): 20-22.
- Bowie, AC, et al. 2022. Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study. *CMAJ*. 194(5): E152-E162.
- Bracken MB. 1986. Drug use in pregnancy and congenital heart disease in offspring. *N Engl J Med*. 314(17):1120.
- Bracken MB, Holford TR. 1981. Exposure to prescribed drugs in pregnancy and association with congenital malformations. *Obstet Gynecol*. 58(3):336-344.
- Brogly SB, et al. 2021. Prenatal opioid analgesics and the risk of adverse birth outcomes. *Epidemiology*. 32(3), 448-456.
- Brogly SB, et al. 2023. Safety of prenatal opioid analgesics: Do results differ between public health insurance beneficiary and population-based cohorts? *Birth Defects Res*. 115(5):555-562.
- Broussard CS, et al. 2011. Maternal treatment with opioid analgesics and risk for birth defects. *Am J Obstet Gynecol*. 204(4):314.e1-11.
- Corsi DJ, et al. 2020. Association of Maternal opioid use in pregnancy with adverse perinatal outcomes in Ontario, Canada, From 2012 to 2018. *JAMA Netw Open*. 3(7):e208256.
- Corsi DJ, et al. 2021. The effects of opioids on female fertility, pregnancy and the breastfeeding mother-infant dyad: A Review. *Basic Clin Pharmacol Toxicol*. 128(5):635-641.
- Esposito, DB, et al. 2022. Characteristics of prescription opioid analgesics in pregnancy and risk of neonatal opioid withdrawal syndrome in newborns. *JAMA Netw Open* 5(8): e2228588.
- Fältmarch S, et al. 2019. Use of opioids during pregnancy and effects of pregnancy outcomes. *Pharmacoepidemiol Drug Saf*. 28: 1239- 1245.
- Fishman B, et al. 2019. Pregnancy outcome following opioid exposure: A cohort study. *PLOS ONE* 14(7): e0219061.
- Flannagan KS, et al. 2020. Is opioid use safe in women trying to conceive? *Epidemiology*. 31(6): 844-851.
- Fronczak CM, et al. 2012. The insults of illicit drug use on male fertility. *Journal of andrology*. 33(4): 515-528.
- Interrante JD, et al. 2021. Prescription opioid use during pregnancy and risk for preterm birth or term low birthweight. *Journal of opioid management* 17(3):215-225.
- Ito S. 2018. Opioids in breast milk: Pharmacokinetic principles and clinical implications. *The Journal of Clinical Pharmacology*, 58: S151-S163.
- Juurink DN, et al. 2012. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: a retrospective cohort study. *Clinical Toxicol*. 50:5.
- Kallen B, Reis M. 2015. Use of tramadol in early pregnancy and congenital malformation risk. *Reprod Toxicol*. 58:246-251.
- Kelly LE, et al. 2013. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. *PLoS ONE*. 8(7):370073.
- Khan K, Chang J. 1997. Neonatal abstinence syndrome due to codeine. *Arch Dis Child*. 76:F59-F60.
- Konijnenberg C, et al. 2022. Verbal and nonverbal memory in school-aged children born to opioid-dependent

- .mothers. *Early human development*, 171, 105614
- Lazaryan M, et al. 2015. Codeine should not be prescribed for breastfeeding mothers or children under the age of 12. *Acta paediatrica* 104(6): 550-556
- Lind JN, et al. 2017. Maternal use of opioids during pregnancy and congenital malformations. A Systematic Review. *Pediatrics*. 139(6):e20164131
- Mactier H, et al. 2020. Prenatal opioid exposure – Increasing evidence of harm. *Early human development*, 150, 105188
- .Mangurten HH. 1980. Neonatal codeine withdrawal in infants of non-addicted mothers. *Pediatrics*. 65:159-160
- .Meny RG, et al. 1993. Codeine and the breastfed neonate. *Journal of human lactation* 9(4): 237-240
- Nair V, et al. 2012. Neonatal withdrawal syndrome due to maternal codeine use. *Paediatr Child Health*. 17(5):e40-e41
- Nezvalová-Henriksen K, et al. 2011. Effects of codeine on pregnancy outcomes from a large population-based cohort study. *Eur J Clin Pharmacol*. 67:1253-1261
- Rothman KJ, et al. 1979. Exogenous hormones and other drug exposures of children with congenital heart disease. *Am J Epidemiol*. 109(4):433-439
- Rubenstein E, et al. 2019. Brief Report: Maternal opioid prescription from preconception through pregnancy and the odds of autism spectrum disorder and autism features in children. *Journal of autism and developmental disorders*, 49(1): 376-382
- .Saxén I. 1975. Associations between oral clefts and drugs taken during pregnancy. *Int J Epidemiol*. 4(1):37-44
- Sachs, Hari Cheryl, and Committee On Drugs. 2013. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. *Pediatrics* 132(3): e796-809
- Shaw GM, et al. 1992. Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy. *Eur J Epidemiol*. 8(5):757-760
- Shaw GM, et al. 1998. Maternal illness, including fever and medication use as risk factors for neural tube defects. *Teratology*. 57(1):1-7
- .Semet M, et al. 2017. The impact of drugs on male fertility: a review. *Andrology*, 5(4), 640-663
- Sujan AC, et al. 2019. Maternal prescribed opioid analgesic use during pregnancy and associations with adverse (birth outcomes: A population-based study. *PLoS Medicine*. 16(12)
- U.S. Food and Drug Administration. 2017. Use of codeine and tramadol products in breastfeeding women – questions and answers. Available at <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/use-codeine-and-tramadol-products-breastfeeding-women-questions-and-answers>. Accessed 2 June 2025
- Van Leeuwen G, et al. 1965. Narcotic withdrawal reaction in a newborn infant due to codeine. *Pediatrics*. 36:635-636
- Varney B, et al. 2024. Opioid analgesic exposure during the first trimester of pregnancy and the risk of major congenital malformations in infants: a systematic review and meta-analysis. *Anaesthesia*. 79(9):967-977
- Willmann, S, et al. 2009. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. *Clin Pharmacol Ther*. 86, 634-643
- Yazdy MM, et al. 2013. Periconceptional use of opioids and the risk of neural tube defects. 2013. *Obstet Gynecol*. 122(4):838-844
- Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. *N Engl J Med*. 313(6):347-352
- Zipursky J, Juurlink DN. 2020. The implausibility of neonatal opioid toxicity from breastfeeding. *Clin Pharmacol Ther*. 108(5):964-970

Codeine

:Selected References

- Aman F, et al. 2012. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. *Lancet Oncol*, 9:256-264
- Amant F, et al. 2019. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. *Ann Oncol*, 30(10):1601-1612
- Aviles A, et al. 2001. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. *Clin Lymphoma*, 2(3):173-177
- Cardonick EH, et al. 2015. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. *Am J Obstet Gynecol*, 212(5):658.e1-658.e8
- de Haan J et al. 2018. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. *Lancet Oncol*, 19:337-346
- Hahn KM, et al. 2006. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. *Cancer*, 107(6):1219-1226
- Huis In 't Veld EA, Van Assche IA, Amant F. Long-term outcomes of children after prenatal exposure to maternal cancer and its treatment. *Acta Obstet Gynecol Scand*. 2024;103(4):757-760
- Ebert U, et al. 1997. Cytotoxic therapy and pregnancy. *Pharmacology & Therapeutics* 74(2):207-220. Hope For Two: The Pregnant with Cancer Network. [Cited 2010 August 16]. Available at URL: <http://www.pregnantwithcancer.org>
- Imai A, et al. 2008. Preservation of female fertility during cancer treatment. *Reprod Med Biol*, 7(1):17-27
- National Cancer Institute. 2009. General information about breast cancer and pregnancy. [Cited 2010 August 16]. Available at URL: <http://www.cancer.gov/cancertopics/pdq/treatment/breast-cancer-and-pregnancy/Patient>
- National Cancer Institute. 2009. Understanding chemotherapy: a guide for patients and families. [Cited 2010 August 16]. Available at URL: <https://www.cancer.org/cancer/treatment-types/chemotherapy.html>
- Ngu SF, et al. 2016. Chemotherapy in pregnancy. *Best Pract Res Clin Obstet Gynaecol*, 33:86-10
- Signorello LB, et al. 2012. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. *J Clin Oncol*, 30(3):239-4
- [Welt CK and Shapiro CL. 2010. Ovarian failure due to anticancer drugs and radiation. [Updated Sep. 2019]

Codeine

:Selected References

- Babuna Kobaner G, Polat Ekinci A. 2020. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case. *Dermatologic Therapy*. 33(4): e13571
- Bendaoud, S, et al. 2024. Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study. *Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*, 56(12), 2038–2044
- Bröms G, et al. 2020. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. *Pharmacoepidemiol Drug Saf*. 29(3):316-327
- Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. *Clin Gastroenterol Hepatol*. 16:99-105.
- Carter JD, et al. 2009. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. *J Rheumatol*. 36(3):635-41.
- Chaparro M, Gisbet JP. 2014. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease. *Expert Opin Drug Saf*. 13(12):1749-62
- Dernoncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). *BioDrugs*. 37(1):73-87
- Geldhof A, et al. 2020. Exposure to infliximab during pregnancy: Post-marketing experience. *Drug Saf*. 43(2):147-161
- Goulden B, et al. 2022. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. *Rheumatology (Oxford)*. 6;61(10):3902-3906
- Grgić, D., et al. 2020. Pregnancy-onset acute severe colitis after in vitro fertilization embryo transfer. Case reports in gastroenterology. 14(3):477-482
- Heller MM, et al. 2011. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. *J Am Acad Dermatol*. 65(4):870
- Kanis SL, et al. 2021. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. *Gut*. 70(7):1266-1274
- Kimberlin, D, et al. 2021. "Rotavirus Infections", Red Book: 2021–2024 Report of the Committee on Infectious Diseases, Committee on Infectious Diseases, American Academy of Pediatrics

- Mahadevan U, et al. 2013. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 11(3):286-92
- Mahadevan U, et al. 2021. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 160(4):1131-1139
- Meserve J, et al. 2021. Paternal exposure to immunosuppressive and/or biologic agents and birth outcomes in patients with immune-mediated inflammatory diseases. Gastroenterology. 161(1):107-115.e3
- Micu MC, et al. 2014. TNF- α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. Rheumatology (Oxford). 53(7):1250-5
- Mouyis M, et al. 2019. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum. 48(5):911-920
- Saougou I, et al. 2013. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine. 80(1):34-37
- Snoeckx Y, et al. 2008. Pregnancy outcomes in women taking infliximab: The infliximab safety database. Arthr Rheum. 58:S426
- Weber-Schoendorfer C, et al. 2015. Pregnancy outcome after TNF- α inhibitor therapy during the first trimester: a prospective multicentre cohort study. British Journal of Clinical Pharmacology. 80(4):727-739

أسئلة؟ اتصل بـ 866.626.6847 اقم بإرسال رسالة نصية 855.999.3525 | البريد الإلكتروني أو الدردشة على MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 مارس، 2025.

Codeine

:Selected References

- American College of Obstetrics and Gynecology. 2018. ACOG Practice Bulletin No. 189: nausea and vomiting of pregnancy. Obstet Gynecol, 131(1):e15-e30
- Arsenault MY, et al. 2002. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can, 24(10):817-831
- Ashkenazi-Hoffnung L, et al. 2013. Evaluation of the efficacy and safety of bi-daily combination therapy with

- .pyridoxine and doxylamine for nausea and vomiting of pregnancy. *Isr Med Assoc J*, 15(1):23-26
- Atanackovic G. 2001. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. *J Clin Pharmacol*, 41(8):842-845
- Banihani S. A. (2017). A Systematic Review Evaluating the Effect of Vitamin B6 on Semen Quality. *Urology journal*, 15(1), 1-5
- Berard A, et al. 2019. New evidence for concern over the risk of birth defects from medications for nausea and vomiting of pregnancy. *J Clin Epidemiol*, 116: 39-48
- Brent RL. 1995. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. *Reprod Toxicol*, 9(4):337-349
- Dayan-Schwartz A, et al. 2024. The efficiency of cabergoline vs pyridoxine for lactation inhibition-a randomized controlled trial. *Am J Obstet Gynecol*. 2024 May;230(5):561.e1-561.e8
- Einarson TR, et al. 1988. A method for meta-analysis of epidemiological studies. *Drug Intell Clin Pharm*, 22:813-824
- Faraoni L, et al. 2020. Doxylamine use in pregnancy and neonatal abstinence syndrome: A case report. *Reprod Toxicol*, 97:6
- Fisher A, et al. 2022. Patterns of antiemetic medication use during pregnancy: a multi-country retrospective cohort study. *Plos One*, 17(12):1-14
- Guala, A, et al. 2022. Vitamin B6 Neonatal Toxicity. *Case reports in pediatrics*, 2022
- Hansen C, et al. 2020. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. *Birth Defects Res*, 112:1234-1252
- He L, et al. 2024 The potential hazards of high doses of vitamin B6 in treating nausea and vomiting in pregnancy: A systematic review. *Int J Gynaecol Obstet*. 10.1002/ijgo.16032
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol*, 168:1393-1399
- Koren G, et al. 2015. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. *BMC Pregnancy Childbirth*, 15:59
- Kutcher JS, et al. 2003. Bendectin and birth defects. II: Ecological analyses. *Birth Defects Res A Clin Mol Teratol*, 67:88-97
- Madjunkova S, et al. 2014. The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin®) for the treatment of nausea and vomiting of pregnancy. *Pediatr Drugs*, 16:199-211
- Matthews A, et al. 2015. Interventions for nausea and vomiting in early pregnancy. *Cochrane Database Syst Rev*, (9):CD007575
- McKeigue PM, et al. 1994. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. *Teratology*, 50:27-37
- Nuangchamnong N, Niebyl J. 2014. Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. *Int J Wom Health*, 6:401-9
- Nulman I, et al. 2009. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and Diclectin. *J Pediatr*, 155(1):45-50
- Nulman I, Koren G. 2009. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age. *Can J Clin Pharmacol*. 16(3):29
- Persaud N, et al. 2018. Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis. *Plos One*, 13(1):e0189978
- Schrager, N. L., et al. & for the National Birth Defects Prevention Study. 2023. The association of nausea and vomiting of pregnancy, its treatments, and select birth defects: Findings from the National Birth Defect Prevention Study. *Birth defects research*, 115(3), 275-289
- Shratch ON, et al. 2024. Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition – A systematic review of clinical trials. *J Gynecol Obstet Hum Reprod*. 2024 Jun;53(6):102783

- Tyl RW, et al. 1988. Developmental toxicity evaluation of Bendectin in CD rats. Teratology, 37:539-552
- Wu, X., et al. 2023. Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 x 2 Factorial Trial. Annals of internal medicine, 176(7), 922-933

أسئلة؟ اتصل بـ 866.626.6847 اقم بإرسال رسالة نصية 855.999.3525 | البريد الإلكتروني أو الدردشة على MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 مارس، 2025.

Codeine

:Selected References

- Ali Sakr Esa W, et al. 2009. Epidural analgesia in labor for a woman with an intrathecal baclofen pump. Int J Obstet Anesth. 2009 Jan;18(1):64-6
- Andrade C. 2020. Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption, J Clin Psychiatry. Aug 4;81(4):20f13606
- Baclofen Product Label. 2023: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04dac0f6-cc6c-4959-9bca-a6e4a99690f3>. Accessed 11/2024
- Balakirouchenane D, et al. 2021. Pharmacokinetics of Baclofen in a Full-Term Newborn after Intrauterine Exposure: A Case Report. Neonatology; 118(5):624-627
- Barker KDD, et al. 2025. Three consecutive pregnancies in a woman with spastic cerebral palsy being treated with intrathecal baclofen therapy. Int J Gynaecol Obstet;168(3):893-895
- Bernard N, et al. 2012. Pregnancy outcomes after in utero exposure to baclofen. Reprod Toxicol; 34(2):157
- Briggs, GG and Freeman RK. 2016. Drugs in Pregnancy and Lactation, Tenth Edition; Wolters Kluwer. 122-3
- Dalton CM, et al. 2008. The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. Mult Scler; 14(4):571-2

- Delhaas EM, Verhagen J. 1992. Pregnancy in a quadriplegic patient treated with continuous intrathecal baclofen infusion to manage her severe spasticity. *Case report. Paraplegia*; 30: 527-8
- Engrand N, et al. 2001. Intrathecal baclofen for severe tetanus in a pregnant woman. *Eur J Anaesthesiol*; 18:261-3
- Eriksson G, Swahn CG. 1981. Concentrations of baclofen in serum and breast milk from a lactating woman. *Scand J Clin Lab Invest*; 41(2):185-7
- Freeman, EH and Delaney, RM. 2016. Neonatal Baclofen Withdrawal: A Case Report of an Infant Presenting with Severe Feeding Difficulties. *J Pediatr Nurs*. May-Jun: 31(3):346-9
- Goldkamp J, et al. 2011. Stiff person syndrome and pregnancy. *Obstet Gynecol*; 118(2 Pt 2):454-457
- Hale TW and Rowe HE. 2015. *Medications and Mother's Milk 2017*. Springer Publishing Co. 93-4
- Hara T, et al. 2018. Pregnancy and breastfeeding during intrathecal baclofen therapy – A case study and review. *NMC Case Rep J*. Jun 25;5(3):65-8
- Hyser, CL and Drake, ME. 1984. Status Epilepticus after Baclofen Withdrawal. *J Natl Med Assoc*; 76(5):533, 537-8
- Lin HH, et al. 2014. Baclofen distribution into breast milk-a potential for toxicity? *J Med Toxicol*; 10:86
- Lin HH, et al. 2014. Prevention of neonatal abstinence syndrome in the setting of intrauterine baclofen exposure. *J Med Toxicol*; 10:85-6
- Logge WB, et al. 2020. Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. *Hum Psychopharmacol*. Mar;35(2):e2722
- Mahdavinassab SM, et al. 2019. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. *Eur Child Adolesc Psychiatry*. Dec;28(12):1619-1628
- Mendez-Lucena C, et al. 2014. Intrathecal baclofen for dystonia treatment during pregnancy: A case report. *Neurologia*; 31(2): 131-132
- Moran LR, et al. 2004. Intrauterine Baclofen Exposure: A Multidisciplinary Approach. *Pediatrics*; 114(2): e267-8
- Morton CM, et al. 2009. Intrathecal baclofen administration during pregnancy: a case series and focused clinical review. *PM R*. Nov;1(11):1025-9
- Mousigian MA, et al. 2022. Neonatal baclofen withdrawal following intrauterine exposure. *J Pediatr Rehabil Med*; 15(2):389-394
- Muñoz FC et al. 2020. Pregnancy outcome in a woman exposed to continuous intrathecal baclofen infusion. *Ann Pharmacother*. Jul-Aug 2000;34(7-8):956
- Ratnayaka BD, et al. 2001. Drug points: Neonatal convulsions after withdrawal of baclofen. *BMJ*. Jul 14;323(7304):85
- Roberts AG, et al. 2003. Intrathecal baclofen pump implantation during pregnancy. *Neurology*; 61:1156-7
- Weatherby SJ, et al. 2004. Pregnancy in stiff-limb syndrome. *Mov Disord*; 19(7):852-4
- Yang K, et al. 2024. Intrathecal baclofen pump in pregnancy: case report, literature review, and management considerations. *Reg Anesth Pain Med*; 49(12):919-922

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider.
MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 مارس، 2025.